Collectively, these findings highlight the significance of TREM2 as a critical regulator of the efferocytosis-TCA cycle-immune metabolites axis in macrophages, suggesting its potential as a promising therapeutic target for restoring cardiac function after myocardial infarction. This evidence concerns the gene TREM2 and myocardial infarction.